ClearPoint Neuro Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat ClearPoint Neuro de winst en omzet met respectievelijk 10.2% en 29.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 12.3% per jaar.

Belangrijke informatie

10.2%

Groei van de winst

12.3%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	29.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

Recent updates

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06

Winst- en omzetgroeiprognoses

NasdaqCM:CLPT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	65	-14	N/A	N/A	1
12/31/2025	39	-16	N/A	N/A	3
12/31/2024	32	-18	N/A	N/A	3
9/30/2024	30	-18	-9	-9	N/A
6/30/2024	28	-18	-10	-9	N/A
3/31/2024	26	-21	-13	-12	N/A
12/31/2023	24	-22	-15	-14	N/A
9/30/2023	22	-22	-17	-16	N/A
6/30/2023	22	-21	-19	-18	N/A
3/31/2023	21	-18	-19	-18	N/A
12/31/2022	21	-16	-17	-16	N/A
9/30/2022	20	-16	-18	-17	N/A
6/30/2022	19	-16	-17	-16	N/A
3/31/2022	17	-16	-15	-15	N/A
12/31/2021	16	-14	-13	-13	N/A
9/30/2021	16	-12	-12	-12	N/A
6/30/2021	15	-9	-10	-10	N/A
3/31/2021	14	-7	-8	-8	N/A
12/31/2020	13	-7	-8	-8	N/A
9/30/2020	12	-7	-6	-6	N/A
6/30/2020	12	-6	-6	-5	N/A
3/31/2020	12	-6	-5	-5	N/A
12/31/2019	11	-6	-3	-3	N/A
9/30/2019	10	-5	-3	-3	N/A
6/30/2019	9	-5	-3	-3	N/A
3/31/2019	8	-6	-3	-3	N/A
12/31/2018	7	-6	-5	-5	N/A
9/30/2018	7	-7	-6	-6	N/A
6/30/2018	7	-7	N/A	-6	N/A
3/31/2018	7	-7	N/A	-7	N/A
12/31/2017	7	-7	N/A	-6	N/A
9/30/2017	7	-7	N/A	-5	N/A
6/30/2017	7	-8	N/A	-5	N/A
3/31/2017	6	-8	N/A	-6	N/A
12/31/2016	6	-8	N/A	-6	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-5	N/A	-6	N/A
3/31/2016	5	-7	N/A	-7	N/A
12/31/2015	5	-8	N/A	-9	N/A
9/30/2015	4	-9	N/A	-9	N/A
6/30/2015	3	-13	N/A	-10	N/A
3/31/2015	4	-11	N/A	-9	N/A
12/31/2014	4	-5	N/A	-7	N/A
9/30/2014	4	-4	N/A	-7	N/A
6/30/2014	4	-4	N/A	-6	N/A
3/31/2014	3	-4	N/A	-7	N/A
12/31/2013	4	-7	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLPT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLPT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLPT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLPT ( 29.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CLPT ( 29.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CLPT naar verwachting over 3 jaar hoog zal zijn

ClearPoint Neuro Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 21% to US$15.67

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

Price target increased by 18% to US$11.83

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Price target increased by 21% to US$15.67

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

ClearPoint Neuro, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Price target increased by 18% to US$11.83

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Insufficient new directors

ClearPoint Neuro, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc.(NasdaqCM:CLPT) dropped from Russell Small Cap Completeness Index

ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory

ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro, Inc. to Report Q1, 2024 Results on May 07, 2024

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

ClearPoint Neuro, Inc., Annual General Meeting, May 15, 2024

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery

President exercised options and sold US$69k worth of stock

New minor risk - Shareholder dilution

ClearPoint Neuro, Inc. to Report Q4, 2023 Results on Mar 12, 2024

ClearPoint Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $15.000011 million.

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering.

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Now 21% undervalued

Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

ClearPoint Neuro, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Consensus EPS estimates fall by 36%

ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

ClearPoint Neuro, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 13%

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target increased by 19% to US$22.00

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Full year 2022 earnings: EPS exceeds analyst expectations

ClearPoint Neuro, Inc. to Report Q4, 2022 Results on Mar 01, 2023

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Year 2023

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Announces First Patient Enrolled in Glioblastoma Trial Using Clearpoint Prism Neuro Laser Therapy System At Skåne University Hospital in Sweden

Price target increased to US$20.25

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2022

ClearPoint Neuro, Inc. to Report Q3, 2022 Results on Nov 08, 2022

ClearPoint Neuro, Inc. Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

ClearPoint Neuro, Inc. Announces Appointment of Mazin Sabra as Chief Operating Officer

ClearPoint Neuro, Inc. Announces FDA Clearance for Software Version 2.1

ClearPoint Neuro: Continuous Great Execution

President notifies of intention to sell stock

ClearPoint Neuro: Picks & Shovels Galore

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?